Akari Therapeutics (AKTX) Total Current Liabilities (2011 - 2026)

Akari Therapeutics has disclosed Total Current Liabilities across 12 years of filings, most recently posting $13.4 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $13.4 million, down 35.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.4 million (down 35.83% YoY), and the FY2025 annual result was $12.4 million, down 37.97% from the prior year.
• Total Current Liabilities came in at $13.4 million for Q1 2026 at Akari Therapeutics, up from $12.4 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $20.9 million in Q1 2025 to a low of $4.6 million in Q4 2023.
• The 4-year median for Total Current Liabilities is $12.9 million (2025), against an average of $12.8 million.
• Across the five-year window, Total Current Liabilities jumped 334.34% in 2024 and sank 37.97% in 2025, its largest moves.
• Akari Therapeutics' Total Current Liabilities stood at $4.6 million in 2023, then surged by 334.34% to $19.9 million in 2024, then tumbled by 37.97% to $12.4 million in 2025, then rose by 8.61% to $13.4 million in 2026.
• The last three Total Current Liabilities figures came in at $13.4 million (Q1 2026), $12.4 million (Q4 2025), and $15.6 million (Q3 2025), per Business Quant data.